[{"id":"a7fa92a7-70a9-4cfd-bed6-1c623c642771","acronym":"BT8009-100","url":"https://clinicaltrials.gov/study/NCT04561362","created_at":"2021-01-18T21:47:25.968Z","updated_at":"2024-07-02T16:35:08.123Z","phase":"Phase 1/2","brief_title":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","source_id_and_acronym":"NCT04561362 - BT8009-100","lead_sponsor":"BicycleTx Limited","biomarkers":" HER-2 • ER • ALK • PGR • ROS1 • NECTIN4","pipe":" | ","alterations":" EGFR mutation • ALK fusion • NECTIN4 expression","tags":["HER-2 • ER • ALK • PGR • ROS1 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • zelenectide pevedotin (BT8009)"],"overall_status":"Recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-23"}]